Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER

Pharmaceutical Investing

Pernix Therapeutics (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL resolving patent litigation related to Zohydro ER. As quoted in the press release: “We are pleased to have settled the outstanding litigation and appeal with Actavis,” said John Sedor, Pernix’s Chairman and Chief Executive Officer. …

“We are pleased to have settled the outstanding litigation and appeal with Actavis,” said John Sedor, Pernix’s Chairman and Chief Executive Officer. “This agreement underscores the strength of our intellectual property around Zohydro^® ER, and aids in reducing litigation costs. We will continue to defend our existing patents, and intend to further expand our intellectual property portfolio around each of our core brands, including Zohydro^® ER.”

Click here to read the full press release.

patent patent litigation patents settlement specialty pharmaceutical specialty pharmaceutical company therapeutics Pharmaceutical Investing